Treatment efficacy and glucose variability control of exenatide versus biphasic insulin aspart 30 in Chinese patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicenter, randomized, open-label, parallel study

被引：0
|
作者：
Liu, Xiangyang [1 ]
Ji, Qiuhe [1 ]
Yang, Wenjuan [2 ]
Liu, Jianrong [3 ]
Gao, Xiling [4 ]
He, Qingzhen [5 ]
Ma, Kaiyan [6 ]
Tian, Zhufang [7 ]
Xie, Xuan [8 ]
机构：
[1] Fourth Mil Med Univ, Xijing Hosp, Dept Endocrinol, Xian, Shaanxi, Peoples R China
[2] Shaanxi Aerosp Hosp, Dept Endocrinol, Xian, Shannxi Provinc, Peoples R China
[3] Xian Chang An Hosp, Dept Endocrinol, Xian, Shannxi Provinc, Peoples R China
[4] Yanan Peoples Hosp, Dept Endocrinol, Yanan, Shannxi Provinc, Peoples R China
[5] Xian Gaoxin Hosp, Dept Endocrinol, Xian, Shannxi Provinc, Peoples R China
[6] Shangluo Cent Hosp, Dept Endocrinol, Shangluo, Shannxi Provinc, Peoples R China
[7] Xian Cent Hosp, Dept Endocrinol, Xian, Shannxi Provinc, Peoples R China
[8] Xi An Jiao Tong Univ, Dept Endocrinol, Affiliated Hosp 2, Xian, Shannxi Provinc, Peoples R China
来源：
DIABETES-METABOLISM RESEARCH AND REVIEWS | 2018年 / 34卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1053987
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Comparison of Blood Glucose Variability Between Exenatide and Biphasic Insulin Aspart 30 in Chinese Participants with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy: A Multicenter, Open-Label, Randomized Trial
    Wang, Li
    Liu, Xiangyang
    Yang, Wenjuan
    Lai, Jingbo
    Yu, Xinwen
    Liu, Jianrong
    Gao, Xiling
    Ming, Jie
    Ma, Kaiyan
    Xu, Jing
    Tian, Zhufang
    He, Qingzhen
    Ji, Qiuhe
    DIABETES THERAPY, 2020, 11 (10) : 2313 - 2328
  • [2] Comparison of Blood Glucose Variability Between Exenatide and Biphasic Insulin Aspart 30 in Chinese Participants with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy: A Multicenter, Open-Label, Randomized Trial
    Li Wang
    Xiangyang Liu
    Wenjuan Yang
    Jingbo Lai
    Xinwen Yu
    Jianrong Liu
    Xiling Gao
    Jie Ming
    Kaiyan Ma
    Jing Xu
    Zhufang Tian
    Qingzhen He
    Qiuhe Ji
    Diabetes Therapy, 2020, 11 : 2313 - 2328
  • [3] A randomized, open-label, multicentre, parallel-controlled study comparing the efficacy and safety of biphasic insulin aspart 30 plus metformin with biphasic insulin aspart 30 monotherapy for type 2 diabetes patients inadequately controlled with oral antidiabetic drugs: The merit study
    Guo, Lixin
    Chen, Li
    Chang, Baocheng
    Yang, Liyong
    Liu, Yu
    Feng, Bo
    DIABETES OBESITY & METABOLISM, 2018, 20 (12): : 2740 - 2747
  • [4] Comparison of exenatide with biphasic insulin aspart 30 on glucose variability in type 2 diabetes: study protocol for a randomized controlled trial
    Shaoyong Xu
    Xiangyang Liu
    Jie Ming
    Qiuhe Ji
    Trials, 17
  • [5] Comparison of exenatide with biphasic insulin aspart 30 on glucose variability in type 2 diabetes: study protocol for a randomized controlled trial
    Xu, Shaoyong
    Liu, Xiangyang
    Ming, Jie
    Ji, Qiuhe
    TRIALS, 2016, 17
  • [6] Efficacy and safety of combination therapy with vildagliptin and metformin versus metformin uptitration in Chinese patients with type 2 diabetes inadequately controlled with metformin monotherapy: a randomized, open-label, prospective study (VISION)
    Ji, L-N
    Pan, C-Y
    Lu, J-M
    Li, H.
    Zhu, D-L
    Li, Q.
    Li, Q-F
    Peng, Y-D
    Tian, H-M
    Yao, C.
    Zhao, Z-G
    Wang, L.
    Wang, B-H
    DIABETES OBESITY & METABOLISM, 2016, 18 (08): : 775 - 782
  • [7] Once-daily initiation with biphasic insulin aspart 30 versus insulin glargine in patients with type 2 diabetes inadequately controlled with oral drugs: an open-label, multinational RCT
    Strojek, Krzysztof
    Bebakar, Wan M. W.
    Khutsoane, Duma T.
    Pesic, Milica
    Smahelova, Alena
    Thomsen, Henrik F.
    Kalra, Sanjay
    CURRENT MEDICAL RESEARCH AND OPINION, 2009, 25 (12) : 2887 - 2894
  • [8] Efficacy and safety of insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Chinese adults with type 2 diabetes: A phase III, open-label, 2:1 randomized, treat-to-target trial
    Yang, Wenying
    Ma, Jianhua
    Hong, Tianpei
    Liu, Ming
    Miao, Heng
    Peng, Yongde
    Wang, Changjiang
    Xu, Xiangjin
    Yang, Tao
    Nielsen, Anne M.
    Pan, Lili
    Liu, Weihong
    Zhao, Weigang
    DIABETES OBESITY & METABOLISM, 2019, 21 (07): : 1652 - 1660
  • [9] Comparative efficacy of exenatide versus insulin glargine on glycemic control in type 2 diabetes mellitus patients inadequately treated with metformin monotherapy
    Karagianni, P.
    Polyzos, S. A.
    Kartali, N.
    Zografou, I
    Sambanis, C.
    ADVANCES IN MEDICAL SCIENCES, 2013, 58 (01): : 38 - 43
  • [10] In inadequately controlled patients with Type 2 diabetes, Biphasic Insulin Aspart 30 combined with Pioglitazone provides better glycaemic control than Biphasic Insulin Aspart 30 monotherapy or Pioglitazone/Sulphonylurea combination.
    Raz, I
    Stranks, S
    Filipczak, R
    Joshi, P
    Lertoft, B
    Råstam, J
    Chow, FC
    DIABETOLOGIA, 2003, 46 : A8 - A8
12345